GlassScriptPhysician profile
Luc Balis
NPI 1578599239
$10,273.13
in general payments reported to CMS, 2019-2025
46 companies · $1,918 in 2025
The $1,918 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $520 · 2021: $1,450 · 2022: $1,536 · 2023: $1,975 · 2024: $1,738 · 2025: $1,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,630.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,049.71 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,049.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $982.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $876.78 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $848.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $665.31 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $362.22 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $271.26 | 2022-2025 | |
| Lilly USA, LLC | $265.70 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $216.05 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.69 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.32 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $201.36 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $200.25 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $191.79 | 2019-2024 | Xarelto, Acclarent Navwire |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luc Balis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.